Osteoporosis in chronic liver disease

Nutrition in Clinical Practice

Volumn 28, Issue 1, 2013, Pages 52-64

  Yadav, Anitha ^a   Carey, Elizabeth J ^a  

^a MAYO CLINIC   (United States)

Author keywords

bone diseases; calcium; liver diseases; liver transplantation; metabolic; osteoporosis; vitamin D; vitamin K

Indexed keywords

ALENDRONIC ACID; BILIRUBIN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; CYTOKINE; DENOSUMAB; ETIDRONIC ACID; FIBRONECTIN; FLUORIDE SODIUM; GLUCOCORTICOID; IBANDRONIC ACID; LEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SOMATOMEDIN C; STRONTIUM RANELATE; TUMOR NECROSIS FACTOR; VITAMIN D; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ALCOHOL CONSUMPTION; BODY MASS; BONE DENSITY; BONE REMODELING; CHRONIC LIVER DISEASE; DIET; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; EPIGASTRIC PAIN; ESOPHAGITIS; ESOPHAGUS ULCER; FLU LIKE SYNDROME; FRACTURE; GENETIC POLYMORPHISM; GRAFT RECIPIENT; HEART ATRIUM FIBRILLATION; HEMOCHROMATOSIS; HEREDITY; HUMAN; HYPOGONADISM; JAW OSTEONECROSIS; LIVER TRANSPLANTATION; MALNUTRITION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NONALCOHOLIC FATTY LIVER; NUTRITIONAL SUPPORT; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VIRUS HEPATITIS; VITAMIN K DEFICIENCY;

ABSORPTIOMETRY, PHOTON; ADRENAL CORTEX HORMONES; BILIRUBIN; BONE DENSITY; CALCITONIN; CALCIUM, DIETARY; DIPHOSPHONATES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER DISEASES; MALNUTRITION; MOTOR ACTIVITY; OSTEOPOROSIS; RALOXIFENE; RANK LIGAND; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN D; VITAMIN K DEFICIENCY;

EID: 84872425526     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533612470145     Document Type: Review

References (90)

1. Collier J. Bone disorders in chronic liver disease. Hepatology. 2007 ; 46: 1271-1278
2. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994 ; 843: 1-129
3. Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol. 2001 ; 35: 316-323
4. Guañabens N, Parés A, Ros I, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol. 2005 ; 42: 573-577
5. Eastell R, Dickson ER, Hodgson SF, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology. 1991 ; 14: 296-300
6. Angulo P, Grandison GA, Fong DG, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology. 2011 ; 140: 180-188
7. Guichelaar MM, Schmoll J, Malinchoc M, et al. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology. 2007 ; 46: 1198-1207
8. Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with noncirrhotic chronic hepatitis B or C infection. World J Gastroenterol. 2005 ; 11: 1843-1847
9. Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S, Sinigaglia L. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int. 2009 ; 20: 549-555
10. Guggenbuhl P, Deugnier Y, Boisdet JF, et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int. 2005 ; 16: 1809-1814
11. Sinigaglia L, Fargion S, Fracanzani AL, et al. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol. 1997 ; 24: 1809-1813
12. Jeon YK, Lee JG, Kim SS, et al. Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women. Endocr J. 2011 ; 58: 87-93
13. Li M, Xu Y, Xu M, et al. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab. 2012 ; 97: 2033-2038
14. Moon SS, Lee YS, Kim SW. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine. 2012 ; 42: 423-429
15. Vargas AA, Acevedo PJM, Domingo GI, et al. Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation. Transplant Proc. 2012 ; 44: 1496-1498
16. Mahmoudi A, Sellier N, Reboul-Marty J, et al. Bone mineral density assessed by dual-energy X-ray absorptiometry in patients with viral or alcoholic compensated cirrhosis: a prospective study. Clin Res Hepatol Gastroenterol. 2011 ; 35: 731-777
17. Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl. 2003 ; 9: 1166-1173
18. Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl. 2006 ; 12: 1390-1402
19. Guañabens N, Cerdá D, Monegal A, et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology. 2010 ; 138: 2348-2356
20. Solaymani-Dodaran M, Card TR, Aithal GP, et al. Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. Gastroenterology. 2006 ; 131: 1752-1757
21. Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet. 2001 ; 357: 342-347
22. Ninkovic M, Skingle SJ, Bearcroft PW, Bishop N, Alexander GJ, Compston JE. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol. 2000 ; 12: 931-935
23. Hay JE. Osteoporosis in liver diseases and after liver transplantation. J Hepatol. 2003 ; 38: 856-865
24. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, et al. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998 ; 28: 695-699
25. Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology. 1987 ; 7: 137-142
26. Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med. 1985 ; 103: 855-860
27. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002 ; 110: 771-781
28. George J, Ganesh HK, Acharya S, et al. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol. 2009 ; 15: 3516-3522
29. Goral V, Simsek M, Mete N. Hepatic osteodystrophy and liver cirrhosis. World J Gastroenterol. 2010 ; 16: 1639-1643
30. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004 ; 292: 490-495
31. Moschen AR, Kaser A, Stadlmann S, et al. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol. 2005 ; 43: 973-983
32. Szalay F, Hegedus D, Lakatos PL, et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol. 2003 ; 38: 395-400
33. García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, et al. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol. 2006 ; 41: 261-266
34. Monegal A, Navasa M, Peris P, et al. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. Liver Int. 2007 ; 27: 492-497
35. Janes CH, Dickson ER, Okazaki R, et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest. 1995 ; 95: 2581-2586
36. Ruiz-Gaspà S, Martinez-Ferrer A, Guañabens N, et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology. 2011 ; 54: 2104-2113
37. Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem. 2001 ; 83: 70-83
38. Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Olivares EG. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab. 2004 ; 89: 4325-4330
39. Springer JE, Cole DE, Rubin LA, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology. 2000 ; 118: 145-151
40. Lakatos PL, Bajnok E, Tornai I, et al. Insulin-like growth factor I gene microsatellite repeat, collagen type Ialpha1 gene Sp1 polymorphism, and bone disease in primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2004 ; 16: 753-759
41. Parés A, Guañabens N, Alvarez L, et al. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology. 2001 ; 33: 554-560
42. Lim LY, Chalasani N. Vitamin D deficiency in patients with chronic liver disease and cirrhosis. Curr Gastroenterol Rep. 2012 ; 14: 67-73
43. Monegal A, Navasa M, Guañabens N, et al. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int. 1997 ; 60: 148-154
44. Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol. 2007 ; 5: 513-520
45. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2010 ; 55: 2624-2628
46. Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007 ; 17: 517-524
47. Barchetta I, Angelico F, Del Ben M, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011 ; 9: 85
48. Tabb MM, Sun A, Zhou C, et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem. 2003 ; 278: 43919-43927
49. Kowdley KV, Emond MJ, Sadowski JA, Kaplan MM. Plasma vitamin K1 level is decreased in primary biliary cirrhosis. Am J Gastroenterol. 1997 ; 92: 2059-2061
50. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000 ; 15: 515-521
51. Szalay F, Folhoffer A, Horváth A, et al. Serum leptin, soluble leptin receptor, free leptin index and bone mineral density in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2005 ; 17: 923-928
52. Verschueren S, Gielen E, O'Neill TW, et al. Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men. Osteoporos Int. :
53. Orsatti FL, Nahas EA, Nahas-Neto J, et al. Low appendicular muscle mass is correlated with femoral neck bone mineral density loss in postmenopausal women. BMC Musculoskelet Disord. 2011 ; 12: 225
54. Langsetmo L, Hitchcock CL, Kingwell EJ, et al. Physical activity, body mass index and bone mineral density-associations in a prospective population-based cohort of women and men: the Canadian Multicentre Osteoporosis Study (CaMos). Bone. 2012 ; 50: 401-408
55. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004 ; 145: 1835-1841
56. Foresta C, Schipilliti M, Ciarleglio FA, Lenzi A, D'Amico D. Male hypogonadism in cirrhosis and after liver transplantation. J Endocrinol Invest. 2008 ; 31: 470-478
57. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology. 2003 ; 125: 941-966
58. Crawford BA, Kam C, Donaghy AJ, McCaughan GW. The heterogeneity of bone disease in cirrhosis: a multivariate analysis. Osteoporos Int. 2003 ; 14: 987-994
59. Trautwein C, Possienke M, Schlitt HJ, et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol. 2000 ; 95: 2343-2351
60. Shiomi S, Masaki K, Habu D, et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. J Gastroenterol. 1999 ; 34: 241-245
61. Crippin JS, Jorgensen RA, Dickson ER, et al. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol. 1994 ; 89: 47-50
62. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002 ; 50: i1-9
63. Guañabens N, Parés A, Monegal A, et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology. 1997 ; 113: 219-224
64. Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology. 2005 ; 42: 762-771
65. Atamaz F, Hepguler S, Karasu Z, et al. The prevention of bone fractures after liver transplantation: experience with alendronate treatment. Transplant Proc. 2006 ; 38: 1448-1452
66. Millonig G, Graziadei IW, Eichler D, et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl. 2005 ; 11: 960-966
67. Kaemmerer D, Schmidt B, Lehmann G, Wolf G, Hommann M, Settmacher U. Monthly ibandronate for the prevention of bone loss in patients after liver transplantation. Transplant Proc. 2012 ; 44: 1362-1367
68. Crawford BA, Kam C, Pavlovic J, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006 ; 144: 239-248
69. Misof BM, Bodingbauer M, Roschger P, et al. Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation. Calcif Tissue Int. 2008 ; 83: 167-175
70. Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol. 2002 ; 37: 93-100
71. Monegal A, Guañabens N, Suárez MJ, et al. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl Int. 2009 ; 22: 198-206
72. Yurci A, Kalkan AO, Ozbakir O, et al. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. Eur J Gastroenterol Hepatol. 2011 ; 23: 1206-1212
73. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010 ; 95: 1555-1565
74. Park W, Lee SH, Park KR, Rho SH, Chung WY, Kim HJ. Characteristics of bisphosphonate-related osteonecrosis of the jaw after kidney transplantation. J Craniofac Surg. 2012 ; 23: e510 - e514
75. Burke MT, Hollett PR, Gray NA. Atypical fractures associated with bisphosphonate use post-renal transplantation. Nephrology (Carlton). 2012 ; 17: 1-4
76. Banaszek D, Morin S. Atypical femur fracture in a liver transplant recipient on long-term bisphosphonate therapy. Can J Gen Intern Med. 2011 ; 6: 153
77. Olsson R, Mattsson LA, Obrant K, Mellström D. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver. 1999 ; 19: 188-192
78. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002 ; 288: 321-333
79. Floreani A, Zappala F, Fries W, et al. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol. 1997 ; 24: 239-244
80. Camisasca M, Crosignani A, Battezzati PM, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology. 1994 ; 20: 633-637
81. Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int. 1995 ; 57: 15-19
82. Levy C, Harnois DM, Angulo P, et al. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int. 2005 ; 25: 117-121
83. Newton J, Francis R, Prince M, et al. Osteoporosis in primary biliary cirrhosis revisited. Gut. 2001 ; 49: 282-287
84. Solerio E, Isaia G, Innarella R, et al. Osteoporosis: still a typical complication of primary biliary cirrhosis?. Dig Liver Dis. 2003 ; 35: 339-346
85. Chen C, Wang S, Jeng F, Lee S. Metabolic bone disease of liver cirrhosis: is it a parallel to the clinical severity of cirrhosis?. J Gastroenterol Hepatol. 1996 ; 11: 417-421
86. Wariaghli G, Mounach A, Achemlal L, et al. Osteoporosis in chronic liver disease: a case-control study. Rheumatol Int. 2010 ; 30: 893-899
87. Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl. 2004 ; 10: 648-653
88. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int. 2001 ; 69: 321-326
89. Choudhary NS, Tomar M, Chawla YK, et al. Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci. 2011 ; 56: 3323-3327
90. Luxon BA. Bone disorders in chronic liver diseases. Curr Gastroenterol Rep. 2011 ; 13: 40-48